ArticleCurrent fungal infection reports2020
Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?
Article in Current fungal infection reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Interpretable Quantitative Structure-Activity Relationship (QSAR) for identification of potent antifungal activity agents towards Candida albicans ATCC 2091.Molecular diversity · 2026Article
- Review of the Microbial Spectrum of Mixed Respiratory Fungal Infections.Journal of epidemiology and global health · 2026Review
- Molecular and Phenotypic Characterization of Multidrug-ResistantJournal of fungi (Basel, Switzerland) · 2026Article
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- Primary Therapy for Invasive Aspergillosis With Triazoles or L-AmB: A Multicenter Retrospective Study.Open forum infectious diseases · 2026Article
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- Phenotypic and Molecular Characterization of Multidrug-Resistant Clinical Isolates of theJournal of fungi (Basel, Switzerland) · 2025Article
- Article
- Antifungals: From Pharmacokinetics to Clinical Practice.Antibiotics (Basel, Switzerland) · 2023Review
- Review
- Article
- Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.Frontiers in immunology · 2022Review
- Review on Plant-Based Management in Combating Antimicrobial Resistance - Mechanistic Perspective.Frontiers in pharmacology · 2022Review
- Are We Ready for NosocomialFrontiers in cellular and infection microbiology · 2021Article
- Examining Signatures of Natural Selection in Antifungal Resistance Genes AcrossFrontiers in fungal biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis review summarizes current treatment options for echinocandin-resistant RECENT
findingsAdvances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant on amphotericin products. Although novel antifungals may provide breakthroughs in the treatment of resistant fungi, these agents are not yet available. Early identification and appropriate treatment remain a paramount, albeit elusive, task. SUMMARY: When either ERC or ARAF are suspected or proven, amphotericin products remain the cornerstone of initial therapy. For ERC, azoles are de-escalation options for susceptible isolates in stable patients to avoid amphotericin toxicities. Although combination echinocandin with high-dose salvage posaconazole or isavuconazole may be attempted in ARAF, it requires careful consideration following patient stabilization. Future research defining optimal therapies and early identification of ERC and ARAF is of extreme importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.